home / stock / mnkd / mnkd quote
Last: | $5.13 |
---|---|
Change Percent: | 0.2% |
Open: | $5.02 |
Close: | $5.13 |
High: | $5.14 |
Low: | $4.92 |
Volume: | 1,629,624 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$5.13 | $5.02 | $5.13 | $5.14 | $4.92 | 1,629,624 | 07-05-2024 |
$5.03 | $5.05 | $5.03 | $5.235 | $4.99 | 876,585 | 07-04-2024 |
$5.03 | $5.05 | $5.03 | $5.235 | $4.99 | 876,585 | 07-03-2024 |
$5.03 | $5.06 | $5.03 | $5.08 | $4.95 | 1,839,509 | 07-02-2024 |
$5.09 | $5.2 | $5.09 | $5.27 | $5.01 | 3,040,165 | 07-01-2024 |
$5.22 | $5.3823 | $5.22 | $5.39 | $5.115 | 5,349,644 | 06-28-2024 |
$5.29 | $5.22 | $5.29 | $5.3 | $5.175 | 1,490,708 | 06-27-2024 |
$5.19 | $5.24 | $5.19 | $5.265 | $5.15 | 2,095,400 | 06-26-2024 |
$5.24 | $5.37 | $5.24 | $5.51 | $5.225 | 2,791,845 | 06-25-2024 |
$5.43 | $5.15 | $5.43 | $5.55 | $5.0858 | 5,539,258 | 06-24-2024 |
$5.11 | $4.9 | $5.11 | $5.14 | $4.87 | 7,078,841 | 06-21-2024 |
$4.86 | $4.8 | $4.86 | $4.975 | $4.75 | 2,188,445 | 06-20-2024 |
$4.78 | $4.76 | $4.78 | $4.8193 | $4.72 | 1,922,537 | 06-19-2024 |
$4.78 | $4.76 | $4.78 | $4.8193 | $4.72 | 1,922,537 | 06-18-2024 |
$4.75 | $4.75 | $4.75 | $4.785 | $4.62 | 2,432,966 | 06-17-2024 |
$4.8 | $5 | $4.8 | $5.01 | $4.74 | 2,691,024 | 06-14-2024 |
$5.04 | $4.73 | $5.04 | $5.13 | $4.71 | 3,467,882 | 06-13-2024 |
$4.73 | $4.7 | $4.73 | $4.8 | $4.69 | 2,308,105 | 06-12-2024 |
$4.65 | $4.43 | $4.65 | $4.66 | $4.42 | 1,583,703 | 06-11-2024 |
$4.49 | $4.58 | $4.49 | $4.6 | $4.36 | 3,202,289 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
Study proves inhaled insulin is as effective as usual care (primarily automated insulin delivery pumps or multiple daily injections) for adults living with T1D meeting the primary endpoint Patients utilizing inhaled insulin reached target A1c (less than 7%) 30% of the time compared to 17%...
17-week endpoint results comparing Afrezza ® head-to-head with multiple daily injections (MDI) and insulin pumps INHALE-3 Study Protocol Chair Dr. Irl. B. Hirsh joined by investigational team to deliver presentation moderated by Jaeb Center founder Dr. Roy W. Beck ...
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation PR Newswire Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket ® inhalation device. Pulmatrix transferring leased building,...